The rise of Viagra and its influence on the medicinal landscape presents a complex question for shareholders. While the early sales data were astounding, the patent has ended, leading to a deluge of generic alternatives that are eroding earnings. Furthermore, the sector is facing challenges related to population trends and evolving healthcare gu… Read More